摘要
目的:探讨新辅助化疗联合术中洛铂腹腔灌注化疗治疗晚期卵巢癌的临床疗效及其对血管内皮生长因子(VEGF)和人附睾蛋白4(HE4)水平的影响。方法:选择2011年1月-2013年6月住院治疗的92例晚期卵巢癌的患者,随机分为观察组和对照组,观察组患者术前采取新辅助化疗联合肿瘤细胞减灭术及术中洛铂腹腔灌注化疗,术后给予TP方案化疗,对照组仅给予常规肿瘤细胞减灭术及术后TP方案化疗,比较2组患者的疗效及毒副反应及其对血清血管内皮生长因子和人附睾蛋白4水平。结果:观察组患者手术时间、术中出血量和腹水量均显著优于对照组(P<0.05)。观察组患者临床总有效率为87.0%,显著优于对照组的56.5%(P<0.05)。2组患者毒副反应相近,经对症处理后均可耐受,2组相比无统计学差异(P>0.05)。2组患者化疗后血清VEGF和HE4水平均显著降低(P<0.05)。而观察组下降更为明显(P<0.05)。结论:术前新辅助化疗联合洛铂术中腹腔灌注化疗治疗晚期卵巢癌临床效果显著,值得在临床上进行推广。
OBJECTIVE To investigate effects of neoadjuvant chemotherapy combined with intraperitoneal perfusion of lobaplatin against advanced ovarian cancer,and impact on levels of serum vascular endothelial growth factor（VEGF）and human epididymis protein 4（HE4）.METHODS A total of 92 patients with advanced ovarian cancer from January 2011 to June 2013 in our hospital were randomly divided into observation group and control group.Patients in observation group took neoadjuvant chemotherapy and cytoreductive surgery,intraoperative lobaplatin CHPP adjuvant chemotherapy,and postoperative TP chemotherapy.Patients in control group received only conventional cytoreductive surgery and postoperative TP chemotherapy.Efficacy,toxicity and serum VEGF and HE4 levels were compared between two groups.RESULTS Operative time,blood loss and ascites in observation group were significantly superior to those in control group（P〈0.05）.Total effective rate in observation group was 87.0%,significantly higher than56.5% of control group（P〈0.05）.Two groups had similar toxicity,which could be tolerated after symptomatic treatment,without significant differences（P〉0.05）.Serum VEGF and HE4 levels in two groups significantly decreased after chemotherapy（P〈0.05）,especially in observation group（P〈0.05）.CONCLUSIONNeoadjuvant chemotherapy combined with lobaplatin intraperitoneal perfusion show significant clinical efficacy against advanced ovarian cancer,and is worthy to be promoted in clinical practice.
出处
《中国医院药学杂志》
CAS
CSCD
北大核心
2016年第7期582-584,602,共4页
Chinese Journal of Hospital Pharmacy
基金
贵州省科学技术基金项目(编号:黔科合J字LKZ[2012]50号)
